Nutex Health (NUTX) has drawn fresh investor attention after opening its 28th hospital nationwide and third facility in Arkansas, expanding emergency care capacity and advanced imaging access in West Little Rock.

For investors, Nutex Health’s latest hospital opening adds to a period of strong momentum, with a 60.35% 90 day share price return and a very large 3 year total shareholder return of 323.60%, alongside a 105.52% total shareholder return over the past year.

If you are looking beyond Nutex Health in the healthcare space, this could be a useful moment to scan for other specialists using the 42 healthcare AI stocks

That kind of swing in Nutex Health’s share price can reflect investors reassessing the business after new hospitals and a sharp earnings turnaround. How much of the move still lines up with the company’s current valuation?

Most Popular Narrative: 28.4% Undervalued

On the most followed narrative, Nutex Health is priced below a fair value estimate of $266.40, compared with the last close at $190.62, which puts the spotlight on what assumptions sit underneath that gap.

The continued shift toward consumer-driven and ambulatory care is expanding Nutex Health's addressable market, with their micro-hospital and freestanding ER model aligning with preferences for convenient, efficient care, supporting enhanced market share and greater revenue per visit over time.

The company's successful navigation of value-based care and risk-based contracts, including rapid expansion of IPAs and population health management capabilities, positions it to benefit from industry reimbursement trends, potentially boosting margins and recurring earnings as the model matures.

Want to see how revenue growth, profit margins and future earnings expectations combine to support that $266.40 figure? The full narrative lays out the earnings path, the margin profile and the valuation multiple that have to line up for Nutex Health to reach that fair value.

Result: Fair Value of $266.40 (UNDERVALUED)

However, Nutex Health’s heavy reliance on arbitration driven revenue and ongoing questions around financial reporting controls could quickly challenge this undervalued narrative if conditions were to shift.

Another View on Nutex Health’s Valuation

The analyst narrative points to Nutex Health trading below a $266.40 fair value based on future earnings and a P/E of 9.3x. The SWS DCF model tells a very different story. It values future cash flows at $15.92 per share, which would leave today’s $190.62 price looking very expensive. Which set of assumptions do you find more realistic for Nutex Health?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nutex Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of optimism and concern around Nutex Health is clear, so this is a good time to review the full picture and decide quickly where you stand. To weigh both sides of the story in one place, start with the 5 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Nutex Health?

If you stop with Nutex Health, you risk missing other opportunities that fit your style. Use the Simply Wall St screener to widen your watchlist intelligently.

• Target potential value opportunities by scanning companies that match the 52 high quality undervalued stocks and see which ones deserve a closer look.
• Strengthen the quality of your portfolio by focusing on businesses identified in the solid balance sheet and fundamentals stocks screener (50 results) that aim for resilience through tougher conditions.
• Spot opportunities others may overlook by reviewing the screener containing 20 high quality undiscovered gems before these stocks land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.